|
30 Sep 2025 |
Eris Lifesciences
|
Consensus Share Price Target
|
1585.90 |
1860.10 |
- |
17.29 |
buy
|
|
|
|
|
25 Oct 2022
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1585.90
|
850.00
|
726.75
(118.22%)
|
Target met |
Buy
|
|
|
|
|
08 Aug 2022
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1585.90
|
825.00
|
696.30
(127.76%)
|
Target met |
Buy
|
|
|
|
|
16 May 2022
|
Eris Lifesciences
|
Motilal Oswal
|
1585.90
|
870.00
|
698.30
(127.11%)
|
|
Buy
|
|
|
|
|
05 May 2022
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1585.90
|
850.00
|
672.15
(135.94%)
|
|
Buy
|
|
|
|
|
05 May 2022
|
Eris Lifesciences
|
Motilal Oswal
|
1585.90
|
870.00
|
670.10
(136.67%)
|
|
Buy
|
|
|
|
|
29 Jan 2022
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1585.90
|
890.00
|
698.50
(127.04%)
|
|
Buy
|
|
|
Industry-wide slowdown in cardiometabolic segment (59% revenue share for ERIS) affected Q3 growth
|
|
27 Dec 2021
|
Eris Lifesciences
|
Motilal Oswal
|
1585.90
|
870.00
|
732.45
(116.52%)
|
|
Buy
|
|
|
|
|
07 Dec 2021
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1585.90
|
975.00
|
723.20
(119.29%)
|
|
Buy
|
|
|
ERIS: Foray into India's insulin market
|
|
06 Dec 2021
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1585.90
|
954.00
|
729.65
(117.35%)
|
|
Buy
|
|
|
our positive stance on ERIS given 1) scheduled potential launches, 2) strong pipeline of patent expiration opportunities and 3) rapidly growing new-generation brands along with power brands in core therapies. ERIS's timely strategy of capacity expansion and higher contribution from chronic/sub-chronic products supported by insignificant regulatory risk, allows it to stand ahead in the industry. We have not factored any revenues and expenses from this JV. Maintain our BUY'...
|
|
06 Dec 2021
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1585.90
|
975.00
|
698.15
(127.16%)
|
|
Buy
|
|
|
ERIS enters ten-year, 70:30 JV with MJ Biopharm for marketing rh-insulin, insulin analogues, GLP1 agonists and biosimilars
|